As strained U.S. hospitals brace for a new surge of COVID-19 cases caused by the fast-spreading omicron variant, doctors are warning of yet another challenge: the two standard drugs they’ve used to fight infections are unlikely to work against the new strain. For more than a year antibody drugs from Regeneron and Eli Lilly have been the go-to treatments for early COVID-19, thanks to their ability to head off severe disease and keep patients out of the hospital. A third antibody from British drugmaker GlaxoSmithKline appears to be the best positioned to fight omicron.
Read full article
Omicron may sideline two leading drugs against COVID-19
